Early Phase 1 Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing to take part and who, or whose legal representative, can sign a consent form agreeing to participate
- Adults aged 18 or older, of any gender
- People who have been newly diagnosed with liver cancer (hepatocellular carcinoma), either with strong clinical suspicion or confirmed diagnosis, and who agree to have a tissue sample taken (if not already done) and/or a special type of scan called an 18F-FDG PET scan
- Healthy volunteers (with no liver cancer diagnosis)
- People who have previously had liver cancer, received treatment, went into remission, and have since had the cancer return
- People who are able and willing to attend scheduled visits, follow the study plan, and complete required tests
Who may not be able to join:
- People who are pregnant or breastfeeding
- People, or whose legal representative, are unwilling or unable to sign the consent form
- People currently experiencing a serious illness affecting the whole body, or who have abnormal levels of salts and minerals in their blood
- People known to have an allergy to the GPC3 imaging agent or its ingredients used in the study
- People whose fasting blood sugar level is above 11.0 mmol/L before receiving the 18F-FDG scan injection
- People who are unable to complete a PET/MR or PET/CT scan — for example, those who cannot lie flat, or who experience claustrophobia or fear of radiation
- People whom the researchers believe may have difficulty following the study requirements, or where other concerns make participation unsuitable (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Xiaoli Lan, PhD, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phone: 0086-027-83692633
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Visual and standardized uptake values assessment of lesions and biodistribution
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.